Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab (Q35895159)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800770%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

title

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800770%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800770%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Igor Puzanov

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800770%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

2

Charles G Drake

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800770%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

11

F Stephen Hodi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800770%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

13

Suzanne L Topalian

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800770%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

14

Drew M Pardoll

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800770%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

David F McDermott

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800770%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Toni K Choueiri

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800770%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

John D Powderly

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800770%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Julie R Brahmer

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800770%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Richard D Carvajal

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800770%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Hans J Hammers

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800770%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Harriet M Kluger

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800770%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Jon M Wigginton

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800770%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Georgia D Kollia

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800770%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Ashok Gupta

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800770%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Dan McDonald

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800770%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Vindira Sankar

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800770%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Jeffrey A Sosman

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800770%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Michael B Atkins

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800770%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Mario Sznol

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800770%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

language of work or name

English

0 references

publication date

30 March 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800770%20AND%20SRC:MED&resulttype=core&format=json

Journal of Clinical Oncology

3 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800770%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800770%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

issue

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800770%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

2013-2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800770%20AND%20SRC:MED&resulttype=core&format=json

In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates

3 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517051

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517051

Nivolumab plus ipilimumab in advanced melanoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517051

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517051

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517051

Molecular mechanisms of T-cell tolerance.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517051

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517051

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517051

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517051

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517051

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517051

Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517051

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517051

PD-1 and its ligands in tolerance and immunity

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517051

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517051

PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517051

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517051

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517051

Sorafenib in advanced clear-cell renal-cell carcinoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517051

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517051

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517051

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517051

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517051

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517051

Toxicity and response criteria of the Eastern Cooperative Oncology Group

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517051

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517051

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517051

Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517051

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

22 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25800770

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1200/JCO.2014.58.1041

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800770%20AND%20SRC:MED&resulttype=core&format=json

release_gml2dirvbrbxtgh26h2ged2qzu

3 March 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/gml2dirvbrbxtgh26h2ged2qzu

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800770%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

PubMed publication ID

25800770

1 reference